$BNGO News
Last published 2d ago
- 2d agoBNGOBionano Reports Third Quarter 2026 Results and Provides a Business UpdateGlobeNewswireConference call today, November 10, 2026, at 4:30 PM ET
- 2d agoBNGOBionano Genomics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2w agoBNGOBionano to Report Third Quarter 2026 Financial Results and Host a Conference Call Webcast on November 10, 2026GlobeNewswireSAN DIEGO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Tuesday, November 10, 2026, at 4:30 p.m. Eastern Time to report
- 1mo agoBNGOBionano Announces Three New Peer-Reviewed Studies Demonstrate Clinical Value of Bionano's Optical Genome Mapping Across Myelodysplastic Syndromes and Acute Myeloid LeukemiaGlobeNewswireSAN DIEGO, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today highlighted three new independently authored, peer-reviewed publications demonstrating the clinical utility of OGM in high-risk
- 2mo agoBNGOBionano Laboratories Announces Proposed Local Coverage Determination (LCD) from MolDX for Genome-Wide Detection of Structural Variants in Hematologic NeoplasmsGlobeNewswireSAN DIEGO, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (NASDAQ:BNGO) that offers CLIA-certified laboratory developed test (LDTs), today announced that
- 2mo agoBNGOBionano Laboratories Announces New York State Department of Health Approval of Lab Developed Tests Based on Optical Genome MappingGlobeNewswireSAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (NASDAQ:BNGO) that offers CLIA-certified laboratory developed test (LDTs), today announced that
- 2mo agoBNGOBionano to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewswireSAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that management will present and host 1x1 meetings at the H.C. Wainwright 28th Annual Global Investment Conference on
- 3mo agoBNGOBionano Reports Second Quarter 2026 Results and Provides a Business UpdateGlobeNewswireSAN DIEGO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today reported financial results for the second quarter ended June 30, 2026. "Our second quarter results reflect a strong vote of
- 3mo agoBNGOBionano to Report Second Quarter 2026 Financial Results and Host a Conference Call Webcast on August 10, 2026GlobeNewswireSAN DIEGO, July 27, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Monday, August 10, 2026, at 4:30 p.m. Eastern Time to report
- 4mo agoBNGOBionano Announces Hiring of Chief Scientific OfficerGlobeNewswireSAN DIEGO, June 24, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO), a leader in genome analysis solutions, today announced the appointment of Alex Hastie, Ph.D., as its Chief Scientific Officer (CSO),
- 4mo agoBNGOBionano Announces 67% Year-Over-Year Growth in Studies Featuring Optical Genome Mapping at ESHG 2026, Reflecting Expanding Global AdoptionGlobeNewswireSAN DIEGO, June 18, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that studies featuring optical genome mapping (OGM) at the 2026 European Society of Human Genetics (ESHG) conference
- 5mo agoBNGOBionano Announces Multiple Publications in 2026 Describing Unique Utility of OGM in Studies of Reproductive Health and Prenatal Genetic DisordersGlobeNewswireSAN DIEGO, June 11, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) announced that to date in 2026, a total of 13 studies analyzing 730 samples were published with key findings that demonstrate the
- 5mo agoBNGOBionano Announces Full Retirement of Outstanding Senior Secured Convertible DebenturesGlobeNewswireSAN DIEGO, May 28, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it has fully retired and cancelled all outstanding Senior Secured Convertible Debentures (the "Debentures").
- 5mo agoBNGOBionano Announces Largest OGM Study of T-Cell Acute Lymphoblastic LeukemiaGlobeNewswireSAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced publication of a peer-reviewed study in Modern Pathology showing that optical genome mapping (OGM) detected genomic
- 6mo agoBNGOBionano Reports First Quarter 2026 Results and Provides a Business UpdateGlobeNewswireSAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today reported financial results for the first quarter ended March 31, 2026. "The Bionano business is healthy, with first quarter
- 6mo agoBNGOBionano Announces Leadership TransitionGlobeNewswireSAN DIEGO, May 06, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that Al Luderer, Ph.D., chairman of Bionano's Board of Directors, has been appointed interim president and chief
- 6mo agoBNGOBionano Announces a 56% Increase in Publications Describing the Utility of OGM in Rare Diseases in Q1 2026 vs Q1 2025GlobeNewswireOverall, studies show: OGM Can Resolve Previously Unresolved Rare Disease CasesOGM Can Serve as a Gold Standard Technique for Characterization of SVs OGM Can Complement Sequencing for Better SV Sensitivity and Genomic
- 6mo agoBNGOBionano to Report First Quarter 2026 Financial Results and Host a Conference Call Webcast on May 13, 2026GlobeNewswireSAN DIEGO, April 29, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Wednesday, May 13, 2026, at 4:30 p.m. Eastern Time to report
- 7mo agoBNGOBionano Announces Publication from Johns Hopkins and MD Anderson Showing that OGM can Outperform Traditional Methods in Analysis of Multiple MyelomaGlobeNewswireSAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) announced the publication of a study in the American Journal of Hematology demonstrating that optical genome mapping (OGM) can
- 7mo agoBNGOBionano Reports Fourth Quarter and Full-Year 2025 Results and Provides Revenue Outlook for 2026GlobeNewswireSAN DIEGO, March 23, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2025. "2025 demonstrated the momentum we
- 8mo agoBNGOBionano to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call Webcast on March 23, 2026GlobeNewswireSAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Monday, March 23, 2026, at 4:30 p.m. Eastern Time to report
- 8mo agoBNGOBionano Symposium 2026 Concluded with 9 Speakers Describing the Breadth of Bionano Solutions and Their Potential for Use on a Large ScaleGlobeNewswireSAN DIEGO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced highlights from the fourth and final day of Symposium 2026. Day 4 featured updates from some of the most advanced and
- 8mo agoBNGO10 Presentations on Day 3 of Bionano Symposium 2026 Showcase OGM's Utility in Unraveling the Complex Puzzles of Constitutional Genetic DisordersGlobeNewswireSAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced highlights from Day 3 of Bionano Symposium 2026, entitled OGM Making its Mark in Constitutional Genetic Disorders.
- 8mo agoBNGO11 Presentations on Day 2 of Bionano Symposium 2026 Showcase Expanding Impact of Optical Genome Mapping Across Oncology and Cell & Gene TherapyGlobeNewswireSAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced highlights from Day 2 of Bionano Symposium 2026, which focused on New Frontiers in Oncology and Bioprocessing
- 8mo agoBNGO9 Presentations Kick Off Day 1 of the Bionano Symposium 2026 Covering Advances in Optical Genome Mapping for Hematologic MalignanciesGlobeNewswireSAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced highlights from Day 1 of the Bionano Symposium 2026 entitled Advancements in Hematologic Malignancies with Optical
- 9mo agoBNGOBionano Announces Bionano Symposium 2026: Global Experts Showcase Advances and Innovation in Optical Genome MappingGlobeNewswireSAN DIEGO, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced Bionano Symposium 2026, the premier global event for the optical genome mapping (OGM) community. This virtual symposium
- 9mo agoBNGOBionano Announces Publication from Sanford Burnham Prebys Medical Discovery Institute Describing use of OGM to Detect Genomic Alterations Introduced by Gene Editing TechnologiesGlobeNewswireSAN DIEGO, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) announced a peer-reviewed study published in Molecular Therapy - Methods & Clinical Development, describing the application of
- 10mo agoBNGOBionano Reports Preliminary Fourth Quarter and Full-Year 2025 ResultsGlobeNewswireSAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today reported certain unaudited preliminary financial results and commercial highlights for the fourth quarter and fiscal year ended
- 11mo agoBNGOBionano Recaps Advances in Optical Genome Mapping Showcased at AMP 2025GlobeNewswireSAN DIEGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics (NASDAQ:BNGO) participated in the Association for Molecular Pathology (AMP) Annual Meeting, held November 11-15, 2025 in Boston, MA. Key presentations at
- 11mo agoBNGOFinal 2026 Clinical Lab Fee Schedule Indicates a 47% Increase in Payment Determination for the Category I CPT Code for OGM use in Hematologic MalignanciesGlobeNewswireSAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (NASDAQ:BNGO) offering CLIA-certified laboratory developed tests (LDTs) based on optical genome
- 12mo agoBNGOBionano Reports Third Quarter 2025 Results and Highlights Recent Business ProgressGlobeNewswireSAN DIEGO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today reported financial results for the third quarter ended September 30, 2025. "Over the last year, we have taken decisive steps to
- 1y agoBNGOBionano Announces Publication Showing OGM Can Overcome Key Limitations of Targeted RNA-Seq for Cytogenetic Investigation in Acute LeukemiaGlobeNewswireSAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced the publication of a study in Cancers from The University of Texas MD Anderson Cancer Center showing how optical genome
- 1y agoBNGOBionano to Report Third Quarter 2025 Financial Results and Host a Conference Call Webcast on November 13, 2025GlobeNewswireSAN DIEGO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Thursday, November 13, 2025, at 4:30 p.m. Eastern Time to report
- 1y agoBNGOBionano Highlights Global Momentum Behind OGM at the 2025 Annual Meeting of the American Society of Human Genetics (ASHG) MeetingGlobeNewswireSAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) participated in The American Society of Human Genetics (ASHG) conference from October 14–18, 2025 in Boston. The event highlighted the
- 1y agoBNGOBionano to Participate in the H.C. Wainwright @ Home EventGlobeNewswireSAN DIEGO, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that Erik Holmlin, PhD, Bionano's president and chief executive officer, will participate in the H.C. Wainwright @ Home
- 1y agoBNGOBionano Genomics, Inc. Announces Closing of $10 Million Public OfferingGlobeNewswireSAN DIEGO, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) ("Bionano" or the "Company") today announced the closing of its previously announced public offering of an aggregate of 5,000,000
- 1y agoBNGOBionano Genomics, Inc. Announces Pricing of $10 Million Public OfferingGlobeNewswireSAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) ("Bionano" or the "Company") today announced the pricing of a public offering of an aggregate of 5,000,000 shares of the Company's
- 1y agoBNGOMultiple Studies Highlighting OGM Utility For Analysis of Cancer Biomarker Chromoanagenesis Published in Dedicated Issue of Methods in Molecular BiologyGlobeNewswireSAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that an issue of the book series Methods in Molecular Biology dedicated to studies of the catastrophic genome
- 1y agoBNGOCMS Posts Preliminary Payment Determination for New Category I CPT Code Covering Use of OGM for Constitutional Genetic DisordersGlobeNewswireSAN DIEGO, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (NASDAQ:BNGO) offering CLIA-certified laboratory developed tests (LDTs) based on optical genome
- 1y agoBNGOBionano to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewswireSAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that Erik Holmlin, PhD, Bionano's president and chief executive officer, will present at the H.C. Wainwright 27th Annual
- 1y agoBNGOBionano Genomics, Inc. (BNGO) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoBNGOBionano Reports Second Quarter 2025 Results and Highlights Recent Business ProgressGlobeNewswireSAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today reported financial results for the second quarter ended June 30, 2025. "We continued to execute on our new strategy of focusing
- 1y agoBNGOBionano Announces Publication Showing Utility of Optical Genome Mapping in Clinical Research of Infant & Toddler T-ALLGlobeNewswireSAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced a peer-reviewed publication from a team led by Manon Delafoy from the Institut Necker Enfants Malades (INEM) and
- 1y agoBNGOBionano to Present at the Canaccord Genuity 45th Annual Growth ConferenceGlobeNewswireSAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that Erik Holmlin, PhD, Bionano's president and chief executive officer, will present at the Canaccord Genuity 45th
- 1y agoBNGOBionano Announces Upgrades to its Software and Compute Platforms to Make Analysis of OGM, Microarray and NGS Data Easier, Faster and More AccurateGlobeNewswireVIA™ 7.2 transforms the workflow for optical genome mapping (OGM) data analysis with AI in constitutional genetic disorders VIA 7.2 supercharges the OGM heme workflow by allowing AI to utilize a lab's historical
- 1y agoBNGOBionano to Report Second Quarter 2025 Financial Results and Host a Conference Call Webcast on August 14, 2025GlobeNewswireSAN DIEGO, July 31, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Thursday, August 14, 2025, at 4:30 p.m. Eastern Time to report
- 1y agoBNGOBionano Recaps Momentum behind Optical Genome Mapping at the Biennial Meeting of the European Cytogenomics Association Held Recently in Leuven, BelgiumGlobeNewswireSAN DIEGO, July 30, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) recently participated in the European Cytogenomics Conference, which is the biennial meeting of the European Cytogenomics Association
- 1y agoBNGOBionano Recaps Global Momentum Behind Optical Genome Mapping at the 2025 Annual Meeting of the European Society of Human Genetics Held Recently in Milan, ItalyGlobeNewswireSAN DIEGO, June 18, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics (NASDAQ:BNGO) recently participated in the European Society of Human Genetics (ESHG) conference held in Milan, Italy, from May 24-27, 2025. The event
- 1y agoBNGOBionano Laboratories Announces a Second Category I CPT Code for OGM Established by the AMA; this one for Use in Whole Genome Analysis for Constitutional Genetic DisordersGlobeNewswireSAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (NASDAQ:BNGO) that offers CLIA-certified laboratory developed tests (LDTs) based on optical genome
- 1y agoBNGOBionano Reports First Quarter 2025 Results and Highlights Recent Business ProgressGlobeNewswireSAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today reported financial results for the first quarter ended March 31, 2025. "The first quarter of 2025 represents the first full